Baird analyst Brian Skorney said that the FDA panel convened yesterday at times made stronger arguments for OCA's approval in PBC than Intercept (ICPT) did adding that to say the meeting "couldn't have gone better is an understatement." Approval of the drug in this indication is "practically certain" and the panelists' agreement that any safety signals could be monitored in the outcomes study removes a significant overhang in NASH, which is "the real opportunity for OCA," Skorney tells investors. Additionally, Skorney noted that Gilead's (GILD) EVP of Clinical Research, John McHutchinson, was in the audience of the committee meeting. The analyst keeps a $332 price target and Outperform rating on Intercept shares.